# BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

> **NCT03355976** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Brown University** · enrollment: 46 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
- Extra Renal Origin
- Clear Cell Adenocarcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03355976
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-30
- **Primary completion:** 2026-06
- **Final completion:** 2026-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03355976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03355976, "BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03355976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*